Related Experiment Videos
Drug to treat obesity: editorial writer responds
Abstract
No abstract available in PubMed .
Related Concept Videos
Articles linked to this work by shared authors, journal, and citation graph.
Troglitazone (Rezulin) and hepatic injury.
Pharmacoepidemiology and drug safety·2002
Effect of onychomycosis on quality of life.
Journal of the American Academy of Dermatology·1998
US adverse drug reaction surveillance 1989-1994.
Pharmacoepidemiology and drug safety·1996
Effects of exposure to benzodiazepine during fetal life.
Lancet (London, England)·1992
Clustering of adverse drug events: analysis of risk factors for cerebellar toxicity with high-dose cytarabine.
Journal of the National Cancer Institute·1992
"Our blood is not pure enough": a qualitative study to understand systemic racial barriers to blood donation for Black people in Canada.
CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne·2026
Experiences of culturally Deaf people with health care access and navigation in Ontario, Canada: a qualitative co-design study.
CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne·2026
[Anatomical variations of peripancreatic veins and surgical strategies].
Zhonghua wai ke za zhi [Chinese journal of surgery]·2026
M4 drug discovery: Human drug predictions from integrated preclinical insights exemplified with a GLP-1R agonist.
European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences·2026
Intranasal delivery of Semaglutide using a thermoresponsive PNPHO nanocarrier: formulation development, characterization and biological evaluation.
International journal of pharmaceutics·2026
Clinical Implementation of Pharmacogenetics-Based Machine Learning Clinical Decision Support Systems: A Scoping Review.
Applied clinical informatics·2026
Substance use-related stigma and injection-related bacterial infections among people who inject drugs in Montreal.
The International journal on drug policy·2026